News

ESPOIR project closing meeting held in Zurich in December 2016

Long-term follow up initiated - the European post-authorisation study on regenerative pulmonary heart valve replacement enrolled 120 patients [more]

Publication about the first ten years of clinical experience with decellularized homografts for pulmonary valve replacement / Patient inclusion to the ESPOIR clinical trial

Surgeons, cardiologists and pediatric cardiologists from Hannover Medical School/Germany and the University Hospital in Chisinau/Moldavia have published the clinical experience derived from ten years of clinical experience using... [more]

Patient inclusion on the increase for the ESPOIR clinical study

The ESPOIR study group, comprising 7 hospitals from Hannover, Chisinau, London, Leuven, Leiden, Padua, Zurich and 4 homograft banks from Brussels, Hannover, Treviso and Rotterdam, has now reached full operative capacity. This has... [more]

Welcome to ESPOIR

Beginning in January 2012, the European Union will fund the European Clinical Study for the Application of Regenerative Heart Valves (ESPOIR) trial, coordinated by the Hannover Medical School, Germany, with a grant of 5.2 Million Euros for a period of four years. The aim of ESPOIR is to transplant a heart valve, which is tolerated by the patient’s immune system, lasts a lifetime and, for children, even holds the potential to grow with the patient.